论文部分内容阅读
目的 探讨米非司酮配伍米索前列醇 2 0 0 μg阴道序贯给药终止孕 10～ 18周妊娠的临床应用价值。 方法 选择孕 10～ 18周要求终止妊娠者 12 2例 ,随机分成A、B、C三组 ,A组 5 6例为羊膜腔注入法 ;B组 3 0例为口服米非司酮及米索前列醇组 ;C组 3 6例为米非司酮口服及米索前列醇经阴道放药组 ,并比较三组流产有效率及有效流产时间。结果 B组、C组流产有效率明显优于A组 (P 均 <0 .0 5 ) ,但B组与C组比较差异无显著性 (P >0 .0 5 ) ,而有效流产时间明显短于A组 (P均 <0 .0 1) ,C组用药剂量及副反应明显少于B组 (P <0 .0 1或 0 .0 5 )。结论 米非司酮配伍米索前列醇 2 0 0 μg阴道序贯给药的流产方法安全、效果好、副反应少 ,适合临床应用
Objective To investigate the clinical value of mifepristone with misoprostol combined with vaginal administration of misoprostol at 10 ~ 18 weeks of gestation. Methods One hundred and twenty-two cases requiring pregnancy termination during 10-18 weeks of gestation were randomly divided into three groups (A, B and C). In group A, 56 cases were treated by amniocentesis. In group B, 30 cases were treated with oral mifepristone and misoprostol Prostatitis group; C group 36 cases of mifepristone oral and misoprostol vaginal discharge group, and compared the three groups of abortion rate and effective abortion time. Results The abortion rates in group B and group C were significantly better than those in group A (P <0.05), but there was no significant difference between group B and group C (P> 0.05), but the effective abortion time was significantly shorter In group A (all P <0.01), the dosage and adverse reactions in group C were significantly less than those in group B (P <0.01 or 0.05). Conclusion Mifepristone combined with misoprostol 200 μg vaginal sequential administration of abortion method is safe, effective, less side effects, suitable for clinical application